Where Will Moderna Be in 3 Years?

As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural for investors to wonder about where the biotech will go in the near future.By early 2028, Moderna will be firmly within its next phase of life, potentially operating more like a traditional pharmaceutical business than like an up-and-coming biotech with a lot to prove about the value of its platform and its general competency in drug development.The question is, will that phase be better than the one it just exited? Let's investigate what it's working on and the financial impacts that work could have for investors.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool